Robert Hershberg, serving as a director at AtaiBeckley Inc. (NASDAQ:ATAI), completed a sale of common stock valued at $496,000 on July 7, 2026. This disposition of shares came on the same day that Mr. Hershberg acquired 100,000 shares through the exercise of stock options. Both the acquisition via option exercises and the subsequent sale of those shares were carried out under a Rule 10b5-1 trading plan. This type of plan permits corporate insiders to establish a predetermined schedule for buying or selling company stock in advance.
The director sold 100,000 shares of AtaiBeckley common stock at a weighted average price of $4.96 per share. The transaction generated total proceeds of $496,000. These shares were sold across multiple transactions, with execution prices ranging from $4.90 to $5.08. At the time of reporting, the stock was trading at $5.32. This current price level reflects a 94% return over the past year. Analysis from InvestingPro suggests that ATAI appears overvalued relative to its Fair Value. The stock has also demonstrated significant volatility, which is noted as one of the key insights available to subscribers.
Earlier on July 7, Mr. Hershberg acquired the 100,000 shares of common stock by exercising fully vested stock options. The options were exercised at a price of $1.35 per share, representing an acquisition value of $135,000. Following these transactions, Mr. Hershberg directly holds 100,000 shares of AtaiBeckley common stock.
In other recent developments, AtaiBeckley Inc. has completed dosing in its Elumina Phase 2b clinical trial for VLS-01, a treatment for adults with treatment-resistant depression. The trial, which involved 156 patients, is set to reveal topline data in the fourth quarter of 2026. Meanwhile, Canaccord Genuity has raised its price target for Atai Life Sciences to $17, citing plans to advance VLS-01 into Phase 3 trials for major depressive disorder. Similarly, Guggenheim increased its price target to $16, highlighting that the company is now fully funded through pivotal readouts expected in early 2029.
Additionally, H.C. Wainwright reiterated a Buy rating with a $25 price target on AtaiBeckley, following a discussion with company management. Canaccord also adjusted its price target to $15, aligning with the expected Phase 3 trials for BPL-003 and upcoming VLS-01 data. These developments indicate ongoing progress in AtaiBeckley’s clinical programs and financial outlook.